RxDoctor Payments Data

Danny Chu, MD

Gastroenterology · New York, NYNPI 1891886842

Payments from drug & device makers

$292,890in general payments, 2019–2025

Across 470 payments — averaging $623.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$219K
  • Madrigal Pharmaceuticals$72K
  • AbbVie$605
  • Fujifilm Healthcare Americas Corporation$255
  • Phathom Pharmaceuticals, Inc.$189
  • Pfizer$181
  • plus $685 from 15 others

What the payments were for

  • Consulting fees$4,8602%
  • Speaking & faculty fees$266,94691%
  • Travel & lodging$5,1112%
  • Food & beverage$15,9735%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$292,890 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$39,385
Medicare patients
92
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide447$644,872
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates302$19,089
Entecavir159$16,795
Tenofovir Disoproxil Fumarate167$15,071
Omeprazole554$4,394
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)19$4,386
Ursodiol46$4,099
Mesalamine ErMesalamine15$847
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl38$543
Clarithromycin15$439
Azathioprine24$278
Esomeprazole Magnesium21$258
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl13$224
Famotidine13$160
Procto-Med HcHydrocortisone12$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$218,817$644,872447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →